Does the media favor SXTP or PRPH?

In the previous week, 60 Degrees Pharmaceuticals had 3 more articles in the media than ProPhase Labs. MarketBeat recorded 4 mentions for 60 Degrees Pharmaceuticals and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -0.28 indicating that ProPhase Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 60 Degrees Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProPhase Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PRPH or NXTS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nexentis Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend CASI or PRPH?

CASI Pharmaceuticals presently has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe CASI Pharmaceuticals is more favorable than ProPhase Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend PRPH or VCNX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PRPH or VCNX more profitable?

Vaccinex has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Vaccinex's return on equity of 0.00% beat ProPhase Labs' return on equity. Company Net Margins Return on Equity Return on Assets ProPhase Labs -825.01% -482.05% -88.90% Vaccinex N/A N/A -383.58%

Do analysts recommend JUNS or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor JUNS or PRPH?

In the previous week, Jupiter Neurosciences had 2 more articles in the media than ProPhase Labs. MarketBeat recorded 3 mentions for Jupiter Neurosciences and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.00 beat Jupiter Neurosciences' score of -0.16 indicating that ProPhase Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jupiter Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProPhase Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ProPhase Labs (PRPH) Competitors

$0.04 0.00 (-0.25%)

As of 08/14/2026 03:47 PM Eastern

Compare

PRPH vs. SXTP, NXTS, CASI, VCNX, and JUNS

Should you buy ProPhase Labs stock or one of its competitors? ProPhase Labs's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTP), Nexentis Technologies (NXTS), CASI Pharmaceuticals (CASI), Vaccinex (VCNX), and Jupiter Neurosciences (JUNS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ProPhase Labs compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, 60 Degrees Pharmaceuticals had 3 more articles in the media than ProPhase Labs. MarketBeat recorded 4 mentions for 60 Degrees Pharmaceuticals and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -0.28 indicating that ProPhase Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProPhase Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60 Degrees Pharmaceuticals currently has a consensus target price of $13.85, suggesting a potential upside of 1,059.00%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than ProPhase Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

60 Degrees Pharmaceuticals has higher earnings, but lower revenue than ProPhase Labs. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.25	-$7.36M	-$8.92	N/A
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.13	N/A

60 Degrees Pharmaceuticals has a beta of 2.54, suggesting that its share price is 154% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

60 Degrees Pharmaceuticals has a net margin of -667.24% compared to ProPhase Labs' net margin of -825.01%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-667.24%	N/A	-129.26%
ProPhase Labs	-825.01%	-482.05%	-88.90%

Summary

60 Degrees Pharmaceuticals beats ProPhase Labs on 9 of the 16 factors compared between the two stocks.

How does ProPhase Labs compare to Nexentis Technologies?

ProPhase Labs (NASDAQ:PRPH) and Nexentis Technologies (NASDAQ:NXTS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

In the previous week, Nexentis Technologies had 2 more articles in the media than ProPhase Labs. MarketBeat recorded 3 mentions for Nexentis Technologies and 1 mentions for ProPhase Labs. Nexentis Technologies' average media sentiment score of 0.75 beat ProPhase Labs' score of 0.00 indicating that Nexentis Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
ProPhase Labs	Neutral
Nexentis Technologies	Positive

ProPhase Labs has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Nexentis Technologies has a beta of 1.83, indicating that its share price is 83% more volatile than the broader market.

Nexentis Technologies has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Nexentis Technologies' return on equity of -304.79% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Nexentis Technologies	N/A	-304.79%	-178.91%

Nexentis Technologies has lower revenue, but higher earnings than ProPhase Labs. Nexentis Technologies is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.13	N/A
Nexentis Technologies	$210K	13.19	-$4M	-$114.15	N/A

9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 61.2% of Nexentis Technologies shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by insiders. Comparatively, 6.5% of Nexentis Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nexentis Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Nexentis Technologies beats ProPhase Labs on 8 of the 13 factors compared between the two stocks.

How does ProPhase Labs compare to CASI Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CASI Pharmaceuticals presently has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe CASI Pharmaceuticals is more favorable than ProPhase Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

CASI Pharmaceuticals has a net margin of -183.93% compared to ProPhase Labs' net margin of -825.01%. CASI Pharmaceuticals' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
ProPhase Labs	-825.01%	-482.05%	-88.90%

In the previous week, ProPhase Labs had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
ProPhase Labs	Neutral

CASI Pharmaceuticals has higher revenue and earnings than ProPhase Labs. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.13	N/A

Summary

CASI Pharmaceuticals beats ProPhase Labs on 11 of the 15 factors compared between the two stocks.

How does ProPhase Labs compare to Vaccinex?

ProPhase Labs (NASDAQ:PRPH) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Vaccinex has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Vaccinex's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Vaccinex	N/A	N/A	-383.58%

ProPhase Labs has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

In the previous week, ProPhase Labs had 1 more articles in the media than Vaccinex. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Vaccinex. ProPhase Labs' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
ProPhase Labs	Neutral
Vaccinex	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vaccinex has lower revenue, but higher earnings than ProPhase Labs. Vaccinex is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.13	N/A
Vaccinex	$388K	5.58	-$20.25M	-$48.27	N/A

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Vaccinex beats ProPhase Labs on 7 of the 13 factors compared between the two stocks.

How does ProPhase Labs compare to Jupiter Neurosciences?

Jupiter Neurosciences (NASDAQ:JUNS) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jupiter Neurosciences has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. ProPhase Labs' return on equity of -482.05% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-241.91%
ProPhase Labs	-825.01%	-482.05%	-88.90%

Jupiter Neurosciences has a beta of 1.99, indicating that its share price is 99% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

In the previous week, Jupiter Neurosciences had 2 more articles in the media than ProPhase Labs. MarketBeat recorded 3 mentions for Jupiter Neurosciences and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.00 beat Jupiter Neurosciences' score of -0.16 indicating that ProPhase Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jupiter Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProPhase Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.4% of ProPhase Labs shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Jupiter Neurosciences has higher earnings, but lower revenue than ProPhase Labs. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20K	201.74	-$8.65M	-$19.12	N/A
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.13	N/A

Summary

ProPhase Labs beats Jupiter Neurosciences on 7 of the 13 factors compared between the two stocks.

Get ProPhase Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRPH vs. The Competition

Export

Metric	ProPhase Labs	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$624K	$11.83B	$7.04B	$13.06B
Dividend Yield	N/A	2.69%	2.56%	10.63%
P/E Ratio	-0.01	641.79	210.89	21.68
Price / Sales	0.12	744.01	603.84	93.83
Price / Cash	N/A	15.13	28.87	38.43
Price / Book	0.02	10.38	11.17	6.52
Net Income	-$53.36M	$2.77B	$3.45B	$346.94M
7 Day Performance	N/A	0.18%	1.17%	1.08%
1 Month Performance	N/A	0.70%	2.18%	1.87%
1 Year Performance	N/A	145.73%	62.39%	20.79%

ProPhase Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRPH ProPhase Labs	0.0794 of 5 stars	$0.04 -0.2%	N/A	-98.9%	$624K	$5.06M	N/A	130	News Coverage Upcoming Earnings Gap Up
SXTP 60 Degrees Pharmaceuticals	2.793 of 5 stars	$1.13 flat	$13.85 +1,125.7%	-77.4%	$3.01M	$1.41M	N/A	3	News Coverage Earnings Report
NXTS Nexentis Technologies	0.7365 of 5 stars	$1.89 +0.5%	N/A	-96.4%	$2.75M	N/A	N/A	2	Short Interest Increase Gap Up
CASI CASI Pharmaceuticals	N/A	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180	News Coverage
VCNX Vaccinex	N/A	$0.96 -3.4%	N/A	+6.3%	$2.49M	$388K	N/A	40	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRPH) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProPhase Labs (PRPH) Competitors

PRPH vs. SXTP, NXTS, CASI, VCNX, and JUNS

How does ProPhase Labs compare to 60 Degrees Pharmaceuticals?

Summary

How does ProPhase Labs compare to Nexentis Technologies?

Summary

How does ProPhase Labs compare to CASI Pharmaceuticals?

Summary

How does ProPhase Labs compare to Vaccinex?

Summary

How does ProPhase Labs compare to Jupiter Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProPhase Labs (PRPH) Competitors

PRPH vs. SXTP, NXTS, CASI, VCNX, and JUNS

How does ProPhase Labs compare to 60 Degrees Pharmaceuticals?

Do institutionals & insiders hold more shares of SXTP or PRPH?

Does the media favor SXTP or PRPH?

Do analysts prefer SXTP or PRPH?

Which has higher earnings & valuation, SXTP or PRPH?

Which has more volatility and risk, SXTP or PRPH?

Is SXTP or PRPH more profitable?

Summary

How does ProPhase Labs compare to Nexentis Technologies?

Does the media refer more to PRPH or NXTS?

Which has more risk and volatility, PRPH or NXTS?

Is PRPH or NXTS more profitable?

Which has higher valuation and earnings, PRPH or NXTS?

Do insiders and institutionals hold more shares of PRPH or NXTS?

Do analysts prefer PRPH or NXTS?

Summary

How does ProPhase Labs compare to CASI Pharmaceuticals?

Do insiders & institutionals have more ownership in CASI or PRPH?

Do analysts recommend CASI or PRPH?

Which has more risk and volatility, CASI or PRPH?

Is CASI or PRPH more profitable?

Does the media prefer CASI or PRPH?

Which has stronger valuation & earnings, CASI or PRPH?

Summary

How does ProPhase Labs compare to Vaccinex?

Is PRPH or VCNX more profitable?

Which has more volatility and risk, PRPH or VCNX?

Does the media refer more to PRPH or VCNX?

Do analysts recommend PRPH or VCNX?

Which has preferable valuation and earnings, PRPH or VCNX?

Do institutionals and insiders hold more shares of PRPH or VCNX?

Summary

How does ProPhase Labs compare to Jupiter Neurosciences?

Do analysts recommend JUNS or PRPH?

Is JUNS or PRPH more profitable?

Which has more risk & volatility, JUNS or PRPH?

Does the media favor JUNS or PRPH?

Do institutionals & insiders hold more shares of JUNS or PRPH?

Which has preferable valuation and earnings, JUNS or PRPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools